Rheoxtech, INC.

Controlled Reperfusion Therapy

Groundbreaking Treatments for the Acute Myocardial Infarction Market

There are over 800,000 heart attacks requiring PCI in the US annually

Up to 50% of the damage is presently untreated despite standard of care interventions

Rheoxtech has the solution

About Rheoxtech

Rheoxtech is a pre-clinical medical device company operating out of Portal Innovations, a life-science business accelerator located in Chicago, IL that is creating groundbreaking treatments for the Acute Myocardial Infarction Market- a wide-ranging group of disease states involving occlusion of major arteries that supply blood to the heart occurring in ~ 800,000 people in the US annually.

Our lead product, the RHEOX™ Reperfusion System aims to mitigate the 30-50% of myocardial infarction (MI) damage that is caused by reperfusion injury, which still occurs after current standard-of-care interventions. The company has 10 wholly owned issued patents for both open heart surgery (CABG) as well as Percutaneous Coronary Intervention (PCI) applications and continues to generate additional IP.

Member Company

Gintaras Vainsys

Co-Founder & CEO

Paul Connors MD, MBA

President & COO

Neil J Thomas MD, MPH

Co-Founder & Heart Surgeon

Giovanni Meier

VP of Engineering

The Team

The Rheoxtech leadership team has over 90 years combined experience in the surgical and medical device fields, built multiple companies, led large cross-disciplinary teams, and has generated 70+ patents, led multiple products through FDA 510(k)/CE Mark/PMA approvals, as well as achieved multiple profitable business exits.

The collective experience and prior success with both the FDA and the commercial market, makes the Rheoxtech executive team uniquely equipped to navigate the complex medical device space and make the RHEOX™ Reperfusion System the next generation leader for treatment of Acute Myocardial Infarction.